CN116940380A - 使用grem1拮抗剂治疗疾病的方法 - Google Patents

使用grem1拮抗剂治疗疾病的方法 Download PDF

Info

Publication number
CN116940380A
CN116940380A CN202280020454.8A CN202280020454A CN116940380A CN 116940380 A CN116940380 A CN 116940380A CN 202280020454 A CN202280020454 A CN 202280020454A CN 116940380 A CN116940380 A CN 116940380A
Authority
CN
China
Prior art keywords
seq
cancer
grem1
sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280020454.8A
Other languages
English (en)
Chinese (zh)
Inventor
朱鹤
钱雪明
高维强
程姹萍
王金名
孙迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Chuangsheng Pharmaceutical Group Co ltd
Shanghai Jiao Tong University
Original Assignee
Suzhou Chuangsheng Pharmaceutical Group Co ltd
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Chuangsheng Pharmaceutical Group Co ltd, Shanghai Jiao Tong University filed Critical Suzhou Chuangsheng Pharmaceutical Group Co ltd
Publication of CN116940380A publication Critical patent/CN116940380A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280020454.8A 2021-03-11 2022-03-11 使用grem1拮抗剂治疗疾病的方法 Pending CN116940380A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/080142 2021-03-11
CN2021080142 2021-03-11
CNPCT/CN2022/076516 2022-02-16
CN2022076516 2022-02-16
PCT/CN2022/080297 WO2022188856A1 (en) 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists

Publications (1)

Publication Number Publication Date
CN116940380A true CN116940380A (zh) 2023-10-24

Family

ID=83226314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280020454.8A Pending CN116940380A (zh) 2021-03-11 2022-03-11 使用grem1拮抗剂治疗疾病的方法

Country Status (11)

Country Link
US (1) US20240190950A1 (https=)
EP (1) EP4304646A4 (https=)
JP (1) JP2024513692A (https=)
KR (1) KR20230156936A (https=)
CN (1) CN116940380A (https=)
AU (1) AU2022233762A1 (https=)
BR (1) BR112023018204A2 (https=)
CA (1) CA3213121A1 (https=)
MX (1) MX2023010594A (https=)
TW (1) TW202300527A (https=)
WO (1) WO2022188856A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117801109A (zh) * 2024-03-01 2024-04-02 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体
WO2024213066A1 (en) * 2023-04-13 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapies involving grem1 antagonists for treatment of cancer
CN119746060B (zh) * 2025-03-07 2025-09-16 南昌大学第一附属医院 一种树突状细胞疫苗制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339063B2 (ja) * 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
ES2898620T3 (es) * 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1
US10844051B2 (en) * 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
PL3806898T3 (pl) * 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117801109A (zh) * 2024-03-01 2024-04-02 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Also Published As

Publication number Publication date
JP2024513692A (ja) 2024-03-27
BR112023018204A2 (pt) 2023-10-24
US20240190950A1 (en) 2024-06-13
KR20230156936A (ko) 2023-11-15
TW202300527A (zh) 2023-01-01
WO2022188856A1 (en) 2022-09-15
EP4304646A4 (en) 2025-05-28
EP4304646A1 (en) 2024-01-17
CA3213121A1 (en) 2022-09-15
MX2023010594A (es) 2023-09-25
AU2022233762A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
CN111213059B (zh) 用于癌症的诊断和治疗方法
CN111363041B (zh) 新型抗-pd-l1抗体
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
TWI526223B (zh) 人化ａｘｌ抗體類
CN106536556B (zh) 结合lgr5的人源化抗体
CN116940380A (zh) 使用grem1拮抗剂治疗疾病的方法
AU2015313268B2 (en) Cancer-cell-specific antibody, anticancer agent, and cancer testing method
JP5858984B2 (ja) ＥｒｂＢ／ＥｒｂＢリガンドに関連する疾患を治療するための分子及びその分子を使用する方法
JP2015221793A (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体
KR20150030675A (ko) 항ｂｍｐ９ 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제
JP6416117B2 (ja) Ｊａｇｇｅｄ１に結合する抗体
CN111315777B (zh) 抗-fgfr4的单克隆抗体
KR20230132544A (ko) 신규한 항-그렘린1 항체
KR20210063330A (ko) 방광암에 대한 치료 및 진단 방법
TW201625301A (zh) 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
EP4115904A2 (en) Anti-rspo3 antibodies
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
JP2024537091A (ja) 少なくともｅｇｆｒに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いｅｇｆｒ発現を有するがんの治療
HK40094175A (zh) 使用grem1拮抗剂治疗疾病的方法
HK40128024A (zh) 双特异性抗egfr/c-met抗体和抗pd-1抗体的组合疗法
HK40032298B (en) Novel anti-pd-l1 antibodies
HK40032298A (en) Novel anti-pd-l1 antibodies
HK40030423B (zh) 用於癌症的诊断和治疗方法
HK1184225A (en) Molecules and methods of using same for treating erbb/erbb ligands associated diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094175

Country of ref document: HK